Responses
Other responses
Jump to comment:
- Published on: 23 November 2015
- Published on: 23 November 2015
- Published on: 23 November 2015Living with pulmonary hypertensionShow More
We thank Drs Herxheimer and Greenhalgh for their interest in our article. Pulmonary hypertension (PH) is a rare and poorly understood disease (as they point out), and our research is the first to provide in- depth insights into the perspective of the patient. Indeed, health-care providers consider the latter as essential in the management of the disease (Guillevin L et al. Eur Respir Rev. 2013 Dec;22(130):535-42 ; Ander...
Conflict of Interest:
None declared. - Published on: 23 November 2015Living with pulmonary hypertensionShow More
This paper happily surprised us by revealing that BMJ Open values ethnography. But it turned out to be an ingenious and well wrapped piece of disease promotion by Bayer who are in the middle of launching a drug to treat it.
The paper mentions no drug and no drug class, only visits to the company website point to it - riciguat (Adempas), the first of a new class of vasodilators called soluble guanylate cyclase (s...
Conflict of Interest:
None declared.